浅述国内外慢病风险评估工具研究进展  

A brief discussion on the research progress of chronic disease risk assessment tools domestically and internationally

作　　者：贺改丽 田磊[1] 王鹏[1] HE Gaili;TIAN Lei;WANG Peng(Health Management Center,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院健康管理中心,北京100191

出　　处：《健康体检与管理》2024年第3期257-263,272,共8页Journal of Health Examination and Management

摘　　要：随着我国经济的发展和生活水平的提高,慢性非传染性疾病(简称慢病)的发病率逐步上升,成为重大公共健康问题。本文综述了国内外慢病风险评估工具的研究进展,重点分析了心血管疾病(CVD)、糖尿病和脑卒中的风险评估工具,并探讨了生物标记物在CVD风险评估中的应用,以及人工智能技术在风险评估中的潜力与挑战。研究表明,多种风险评估工具能有效预测个体的慢病发病风险,但同时也存在数据依赖性、透明度和可解释性问题、技术局限性与误判风险等挑战。未来研究应注重工具的个性化和精准化,加强跨学科合作和技术创新,提高公众对慢病风险评估工具的认知和使用率。With the development of China's economy and the improvement of living standards,the incidence of chronic non-communicable diseases(NCD)has been gradually increasing,becoming a significant public health issue.This paper reviews the research progress of NCD risk assessment tools at home and abroad,focusing on the risk assessment tools for cardiovascular diseases,diabetes,and stroke,and discusses the application of biomarkers in cardiovascular disease risk assessment,as well as the potential and challenges of artificial intelligence technology in risk assessment.Studies have shown that various risk assessment tools can effectively predict individuals'risks of NCD,but there are also challenges such as data dependency,transparency and interpretability issues,technical limitations,and risk of misjudgment.Future research should focus on the personalization and precision of tools,strengthen interdisciplinary cooperation and technological innovation,and improve public awareness and usage of NCD risk assessment tools.

关 键 词：慢性非传染性疾病 心血管疾病 糖尿病 脑卒中 风险评估工具 

分 类 号：R195.4[医药卫生—卫生统计学]